{
    "clinical_study": {
        "@rank": "3067", 
        "arm_group": [
            {
                "arm_group_label": "1 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 1 mg/kg every 2 weeks"
            }, 
            {
                "arm_group_label": "2 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 2 mg/kg every 2 weeks"
            }, 
            {
                "arm_group_label": "0.2 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 0.2 mg/kg every 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients will be enrolled into one of three PRX-102 dosing groups (0.2 mg/kg, 1.0 mg/kg, 2.0\n      mg/kg), to receive the same dose they had received in Phase 1/2 study PB-102-F01, and will\n      continue to receive PRX-102 as an intravenous infusion every 2 weeks for 38 weeks."
        }, 
        "brief_title": "An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Fabry Disease", 
        "condition_browse": {
            "mesh_term": "Fabry Disease"
        }, 
        "detailed_description": {
            "textblock": "Patients will be enrolled into one of three PRX-102 dosing groups (0.2 mg/kg, 1.0 mg/kg, 2.0\n      mg/kg) to receive the same dose they had received in the Phase 1/2 study, PB-102-F01, and\n      will continue to receive intravenous infusions of PRX-102 every 2 weeks for 38 weeks (9\n      months).\n\n      All exploratory endpoints that were evaluated during the Phase 1/2 study PB-102-F01 will\n      continue to be assessed in the extension protocol (study PB-102-F02).\n\n      The additional exploratory efficacy parameters that were evaluated at baseline of the Phase\n      1/2 study PB-102-F01 as a reference point, before the initiation of treatment, will be\n      evaluated after 3 months into the extension study (total treatment of 6 months). These\n      parameters include Gb3 concentration in renal and skin tissues, LVM, MSSI and cardiac\n      function tests (echocardiography and stress test). Cerebrovascular disease (clinical and\n      MRI) will be evaluated at last infusion (total treatment of 12 months)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completion of Phase 1/2 study PB-102-F01\n\n          -  The patient signs informed consent\n\n          -  Female patients and male patients whose co-partners are of child-bearing potential\n             agree to use a medically acceptable method of contraception, not including the rhythm\n             method\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing\n\n          -  Presence of any medical, emotional, behavioral or psychological condition that, in\n             the judgment of the Investigator and/or Medical Director, would interfere with the\n             patient's compliance with the requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01769001", 
            "org_study_id": "PB-102-F02"
        }, 
        "intervention": {
            "arm_group_label": [
                "1 mg/kg", 
                "2 mg/kg", 
                "0.2 mg/kg"
            ], 
            "description": "Comparison of different doses of drug", 
            "intervention_name": "PRX-102", 
            "intervention_type": "Drug", 
            "other_name": "plant cell expressed recombinant human alpha-galactosidase-A"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Fabry disease", 
            "Alpha galactosidase deficiency", 
            "Metabolic storage disease"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Department of Human Genetics, Emory University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75226"
                    }, 
                    "name": "Research Baylor Institute of Metabolic Disease"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22030"
                    }, 
                    "name": "O & O Alpan LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Australia", 
                        "zip": "3050"
                    }, 
                    "name": "Royal Melbourne Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asuncion", 
                        "country": "Paraguay"
                    }, 
                    "name": "Hematology and Clinical Research Private Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2QG"
                    }, 
                    "name": "The Royal Free Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Paraguay", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients", 
        "overall_official": {
            "affiliation": "Protalix Biotherapeutics", 
            "last_name": "Einat Almon, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse events reported by the patient and from monitoring with clinical laboratory, physical examination, ECG", 
            "measure": "Number of participants with adverse events as a measure of safety", 
            "safety_issue": "Yes", 
            "time_frame": "38 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01769001"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Gb3 concentrations in plasma and urine sediment", 
                "measure": "Gb3 concentrations", 
                "safety_issue": "No", 
                "time_frame": "38 weeks"
            }, 
            {
                "description": "Measurement of glomerular filtration", 
                "measure": "Glomerular filtration rate", 
                "safety_issue": "No", 
                "time_frame": "38 weeks"
            }, 
            {
                "description": "Short term brief pain inventory", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "38 weeks"
            }, 
            {
                "description": "Measure of kidney function", 
                "measure": "Proteinuria", 
                "safety_issue": "No", 
                "time_frame": "38 weeks"
            }
        ], 
        "source": "Protalix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Protalix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}